Protein can improve targeting of ovarian cancer drug, scientists say
Tuesday 11 December 2007
Scientists have discovered a protein which could improve the success rate of one of the most common drugs used to fight ovarian cancer, according to a new study.
Researchers funded by Cancer Research UK and the Medical Research Council found that the loss of a protein called TGFBI caused paclitaxel to fail.
The drug is a common chemotherapy treatment for ovarian cancer but only half of patients with the disease respond well to the therapy.
Experts based at the Cambridge Research Institute at Cambridge University looked at ovarian cancer cell lines and data from 20 patients in a prospective trial.
Those who showed no response to the drug had less TGFBI in their pre-treatment samples, compared with those whose condition improved.
Post-treatment studies showed that the death of cancer cells happened when there were high levels of the protein.
The study of 20 patients at Addenbrooke's Hospital suggests that patients who lack the protein could be spared chemotherapy that will not benefit them.
Dr James Brenton, lead researcher and clinician, said: "TGFBI is lost in one third of primary ovarian cancers and it is possible that this protein could be used as a biomarker for selecting patients likely to respond to this class of drug.
"Our findings offer hope not only for improved ovarian cancer treatment, it may also lead to improvements in the success rate of other taxane drugs used to treat lung and breast cancer."
Prof Herbie Newell, Cancer Research UK's director of translational research, said: "We are entering a period of cancer treatment where more drugs are targeted at those people who will benefit the most.
"This personalised medicine approach potentially means treatments will be more effective with fewer side effects.
"This is really important for diseases like ovarian cancer that can be challenging to treat."
Exclusive: World’s most pristine waters are polluted by US Navy human waste
Saint Patrick's Day: Google Doodle celebrates patron saint of Ireland - here are 10 things you didn't know about the man himself
Missing Malaysia Airlines Flight MH370: Did jetliner fly into area controlled by Taliban? Net widens after claims final satellite signal could have been sent from the ground
Britain’s five richest families worth as much as poorest 20 per cent, says Oxfam
Nasa-funded study warns of ‘collapse of civilisation’ in coming decades
Ukip and Nigel Farage on course for remarkable victory in European elections
Katie Hopkins continues campaign to become Britain's most hated talking head with poorly timed Bob Crow tweet
Tony Benn was entirely ineffectual - and usually wrong
No EU referendum under Labour: Ed Miliband to reveal that vote on membership is ‘unlikely’ in next Parliament if party wins power
The rise of Ukip: Study warns Labour that Eurosceptic party's electoral base now 'more working class than any of the main parties'
Europeans have ‘got whiter’ due to natural selection in past 5,000 years, scientists say
- 1 Is your name now 'banned' in Saudi Arabia?
- 4 Nasa-funded study warns of ‘collapse of civilisation’ in coming decades
£44000 per annum + Benefits: Pro-Recruitment Group: A Top 10 practice in the h...
£50000 - £60000 Per Annum: Clearwater People Solutions Ltd: PMO Lead - £50k - ...
£21000 - £35000 per annum: Randstad Education Cambridge: Randstad are currentl...
£45000 - £70000 per annum: Pro-Recruitment Group: We are working with an accou...